Pfizer Inc. (PFE) is opening its wallet again. On Wednesday, the drugmaker announced an exclusive licensing agreement with Starna Therapeutics that could be worth up to $2.63 billion in upfront and milestone payments, plus royalties. The deal expands Pfizer's inflammation and immunology pipeline and gives it a stronger foothold in next-generation cell therapies.
Pfizer Bets $2.63 Billion on a CAR-T That Works Inside Your Body
Get Pfizer Alerts
Weekly insights + SMS alerts
The Money and the Mechanics
Starna gets $330 million upfront. The biotech is also eligible for up to $2.3 billion in development and commercial milestone payments, plus royalties on net sales of approved products. That's the classic biotech deal structure: a decent chunk of cash now, a lottery ticket later.
Under the agreement, Pfizer gains exclusive rights outside Greater China to develop, manufacture, and commercialize three early-stage CAR-T cell therapy programs targeting autoimmune diseases. Pfizer will lead clinical development outside Greater China and plans to manufacture finished drug products for initial clinical trials at its U.S. facilities. It also retains exclusive control over commercialization outside Greater China, with options to expand its rights into the region.
What Is In Vivo CAR-T Anyway?
The agreement gives Pfizer access to Starna's proprietary in vivo CAR-T technology for applications in inflammation, immunology, and oncology. CAR-T therapy involves reprogramming immune cells to target specific disease-causing cells. The in vivo approach aims to do this directly inside the patient's body, which could be a big deal if it works.
Pfizer also secured options to exclusively license compounds developed through a separate research collaboration. But here's the catch: the three initial programs remain at the pre-investigational new drug application stage. That means they're still in very early development. This is a long-term bet, not a near-term revenue driver.
Why Pfizer Likes the Science
Michael Vincent, Pfizer's chief inflammation and immunology officer, said the technology could address the needs of autoimmune disease patients who have limited treatment options. He highlighted Pfizer's global experience in developing and manufacturing RNA-based medicines as a key advantage in advancing Starna's programs.
Meanwhile, Starna CEO Rongkuan Hu said the company's targeted lipid nanoparticle delivery platform and RNA technology provide a foundation for developing in vivo CAR-T therapies. The partnership combines Pfizer's expertise in immunology, drug development, and commercialization with Starna's RNA delivery technology. It also opens opportunities to develop new treatments for autoimmune diseases and cancer.
PFE Price Action: Pfizer shares were down 1.28% at $28.10 at the time of publication on Wednesday, according to market data.
More News

Dow Drops as Nvidia Slips After Earnings, Dollar Hits 19-Month High: Stock Market Today

Fed Minutes: 'Almost All' Officials See More Hikes, and AI Debt Is Now on the Radar

Nvidia's $105 Billion OpenAI Bet Comes With a 20-Year Catch

Waller Warns of a December Rate Shock. Here's How TIPS ETFs Handle That Kind of Heat.

Wall Street Says the AI Trade Is Dead. ETF Investors Are Quietly Buying the Dip

Bitcoin's Next Stop: $54,000, $38,000, Or A Surprise Rebound?

Lowe's Q3 Beat Came With a Tariff Refund Twist, and JPMorgan Says 2026 Is the Clean Slate for 2027

Newmont Stock Sinks 6% as Gold Loses Its Shine Below $3,800
Get Pfizer Alerts
Real-time alerts on price moves, news, and trading opportunities.
Join 20,000+ investors. No spam, ever.
Featured Articles
View all news
Dow Drops as Nvidia Slips After Earnings, Dollar Hits 19-Month High: Stock Market Today

Fed Minutes: 'Almost All' Officials See More Hikes, and AI Debt Is Now on the Radar

Nvidia's $105 Billion OpenAI Bet Comes With a 20-Year Catch

Waller Warns of a December Rate Shock. Here's How TIPS ETFs Handle That Kind of Heat.

Wall Street Says the AI Trade Is Dead. ETF Investors Are Quietly Buying the Dip

Bitcoin's Next Stop: $54,000, $38,000, Or A Surprise Rebound?

Lowe's Q3 Beat Came With a Tariff Refund Twist, and JPMorgan Says 2026 Is the Clean Slate for 2027






